Modality | HD | PD | TX | |
Reference | ||||
Moradpour et al 43 | 0.72 | 0.75 | 0.82 | |
Rosselli et al 44 | 0.576 | 0.668 | 0.796 | |
Jensen et al 45 | 0.44 | 0.65 | 0.86 | |
Shimizu et al 9 | 0.44 | 0.53 | LT: 0.71 | DT: 0.57 |
Villa et al 12 | 0.69 | 0.69 | 0.81 | |
Haller et al 13 | 0.66 | 0.81 | 0.9 | |
Howard et al 11 | 0.55 | 0.55 | First-year TX utility 0.73 | Second-year TX utility 0.70 |
Kontodimopoulos et al 46 | 0.639 | 0.599 | 0.716 | |
de Wit et al 47 | 0.66 | 0.71 | 0.9 | |
Average | 0.60 | 0.66 | 0.77 | |
This study | 0.61 | 0.61 | 0.73 |
DT, deceased-donor transplantation; HD, haemodialysis; LT, living-donor transplantation; PD, peritoneal dialysis; RRT, renal replacement therapy; TX, renal transplantation.